Use of BNP and NT-proBNP to Rule In and Rule Out Heart Failure
**For ruling out heart failure, use BNP <100 pg/mL or NT-proBNP <300 pg/mL, which effectively excludes the diagnosis with a 99% negative predictive value.** For ruling in heart failure, use age-stratified NT-proBNP thresholds or BNP >500 pg/mL to confirm the diagnosis with high specificity 1.
Algorithmic Approach to Using Natriuretic Peptides
Step 1: Rule-Out Thresholds (Highest Priority)
When evaluating a patient with dyspnea or suspected heart failure:
- BNP <100 pg/mL: Heart failure is effectively ruled out (83% diagnostic accuracy, negative predictive value 99%) 1
- NT-proBNP <300 pg/mL: Heart failure is ruled out regardless of age (negative predictive value 99%) 1
These low values allow you to confidently exclude heart failure and pursue alternative diagnoses such as pulmonary disease, pulmonary embolism, or other causes of dyspnea 1.
Step 2: Intermediate Zone (Gray Zone)
When values fall in the intermediate range, heart failure is possible but not confirmed:
- BNP 100-500 pg/mL: Consider alternative diagnoses including chronic LV dysfunction, lung disease, or pulmonary embolism 1
- NT-proBNP 300-450 pg/mL (age <50 years): Heart failure possible, requires confirmatory testing 1
- NT-proBNP 300-900 pg/mL (age 50-75 years): Heart failure possible, requires confirmatory testing 1
- NT-proBNP 900-1800 pg/mL (age >75 years): Heart failure possible, requires confirmatory testing 1
In this zone, proceed to echocardiography or other cardiac imaging for definitive diagnosis 1.
Step 3: Rule-In Thresholds
When values exceed these thresholds, heart failure is very likely:
- BNP >500 pg/mL: Heart failure is very likely 1
- NT-proBNP >450 pg/mL (age <50 years): Heart failure is very likely 1
- NT-proBNP >900 pg/mL (age 50-75 years): Heart failure is very likely 1
- NT-proBNP >1800 pg/mL (age >75 years): Heart failure is very likely 1
At these levels, initiate heart failure management while confirming with echocardiography 2.
Comparative Performance: BNP vs NT-proBNP
Both biomarkers perform similarly for ruling out heart failure, with no statistically significant difference in diagnostic accuracy at rule-out thresholds 3. A 2015 meta-analysis demonstrated sensitivities approaching 1.0 for both tests at their respective lower cut-offs 3. However, NT-proBNP may have slightly better diagnostic accuracy in primary care settings (AUROC 89.9% vs 85.9% for BNP) 4.
The 2022 AHA/ACC/HFSA guidelines give Class I, Level A recommendations for using either BNP or NT-proBNP to support diagnosis or exclusion of heart failure in patients presenting with dyspnea 2.
Critical Caveats and Pitfalls
Conditions Causing Falsely Elevated Levels:
- Age: Levels increase with age; use age-adjusted thresholds for NT-proBNP 1
- Female sex: Women have higher baseline levels 1
- Renal failure: Elevates both peptides; adjust cut-points upward 1
- Atrial fibrillation: Increases levels independent of heart failure 1
- Pulmonary disease, malignancy, beta-blocker therapy: All can elevate levels 1
Conditions Causing Falsely Low Levels:
- Obesity: Significantly reduces BNP and NT-proBNP levels, decreasing diagnostic sensitivity 1, 2
- Flash pulmonary edema: Insufficient time for ventricular production and release 1
In obese patients, use lower thresholds or rely more heavily on clinical assessment and imaging 2.
Clinical Context Matters
BNP/NT-proBNP testing is most useful when clinical evaluation is equivocal—when history, physical examination, and chest radiograph are suggestive but not clearly diagnostic of heart failure 1. The Canadian IMPROVE-CHF trial demonstrated that combining NT-proBNP with clinical judgment significantly outperforms clinical judgment alone (AUC 0.904 vs 0.834, P<0.00001) 1.
Special Population: Heart Failure with Preserved Ejection Fraction (HFpEF)
Natriuretic peptides are particularly valuable for diagnosing HFpEF, where echocardiography shows normal ejection fraction but patients have diastolic dysfunction. BNP levels are elevated in HFpEF with an area under the ROC curve of 0.92-0.96 for detecting diastolic dysfunction 1. However, BNP cannot differentiate between systolic and diastolic dysfunction—levels tend to be lower in HFpEF than in heart failure with reduced ejection fraction 1.
Prognostic Value
Beyond diagnosis, elevated BNP and NT-proBNP levels at hospital admission strongly predict mortality and rehospitalization 2. A BNP >480 pg/mL predicts a 51% six-month probability of heart failure events, while BNP <230 pg/mL indicates excellent prognosis with only 2.5% event rate 1. Predischarge levels inform trajectory and establish postdischarge prognosis (Class 2a recommendation) 2.
Summary Algorithm
- Measure BNP or NT-proBNP in patients with dyspnea or suspected heart failure
- If BNP <100 pg/mL or NT-proBNP <300 pg/mL: Rule out heart failure, pursue alternative diagnoses
- If intermediate values: Proceed to echocardiography; consider alternative diagnoses
- If BNP >500 pg/mL or age-adjusted NT-proBNP thresholds exceeded: Diagnose heart failure as very likely, initiate treatment, confirm with imaging
- Adjust interpretation for obesity (lower thresholds), renal failure (higher thresholds), age, and sex
- Use for risk stratification: Higher levels predict worse outcomes and guide intensity of follow-up 2